AACR: Germany's small NK cell player Affimed makes a big splash with early lymphoma data
German small-cap Affimed has long been highlighted as a potential Cinderella story, winning milestone-rich deals with Genentech and Roivant. And on Friday the biotech continued its NK cell march, presenting the first look at in-human data ahead of this weekend’s AACR conference.
Researchers saw significant disease reduction in all four lymphoma patients dosed with Affimed’s experimental off-the-shelf NK cell therapy, with two registering complete responses as of the March 31 data cutoff, the company announced. All of the patients had been heavily pretreated — with a range of four to 14 lines of prior therapy — and there were no signs of cytokine release syndrome, toxicity or graft-versus-host disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.